saman rahmanian

Co-Founder and Chief Product Officer of @Ro, Co-Founder of @managedbyq, Partner at @prehype - I don't post on X; Hit me on LinkedIn

[saman rahmanian @saman]

@public LFG!!

[saman rahmanian @saman]

BIG NEWS! 🚀🚀🚀

Today, we're announcing that we're working with @EliLillyandCo to expand access to Zepbound vials.

https://t.co/AIiOSAtdjk

Every day we fight to give our patients the easiest and most effective healthcare possible. Ro’s work with Lilly making Zepbound single-dose vials seamlessly available through @ro is a big step toward that goal.

Integrating Ro’s platform with LillyDirect means that we offer an end-to-end experience pairing access to Zepbound single-dose vials with everything patients need to achieve their health goals – from diagnosis to delivery of medication and ongoing care.

Ro has always believed in the ability of our direct-to-patient platform to transform healthcare for millions of patients, and it’s incredibly exciting to work with a leader like Lilly to expand access to their life-changing, FDA-approved medicines.

[saman rahmanian @saman]

While we’ve built ro.OS over the past six years, now we’re excited to share more about this technology, how we built it, and how it’s helped millions of patients more easily and effectively achieve their health goals. https://t.co/5KxWRvZmRS

[saman rahmanian @saman]

I am so proud to give people a look under the hood here at Ro and show off ro.OS — the @Ro Operating System. https://t.co/z1iWydXzln

[saman rahmanian @saman]

That’s exactly what we set out to do at Ro. ro.OS, our technology platform integrates the core parts of the healthcare system – bringing together nationwide telehealth, pharmacy, and lab services powered by four end-user applications and a suite of proprietary tools and features.

[saman rahmanian @saman]

High-quality care shouldn’t be a handmade luxury good. As a society, the only way that we have turned luxuries that only the few can access into commodities that everyone can access is through technology.

[saman rahmanian @saman]

Awesome article on the far-reaching effects of GLP-1s across many industries by the one and only @ZReitano

[Z Reitano @ZReitano]

Food For Thought: The Potential Ripple Effect of GLP1s. Hope it’s as interesting to read as it was to write.

https://t.co/CQqvoG2rEw

[Z Reitano @ZReitano]

The Wegovy shortage and Full Ownership
https://t.co/SYysa6Rsz6

[saman rahmanian @saman]

People with obesity want to lose weight, are motivated to improve their health, and dedicated to sticking with what it takes to do so–but they need better care and support. Read more insights from @Ro’s survey with @ObesityAction: https://t.co/mI4q3TMQpS

[saman rahmanian @saman]

An incredibly thoughtful Q&A from @ZReitano on the questions driving the discourse around obesity and GLP-1s today. It's well worth the read to better understand this complex condition and the available treatments based on the data and science.

[Z Reitano @ZReitano]

1/ Decided to publish “Obesity: An Accusation Audit”. Started as an internal resource for @ro but posting it bc I’ve seen the public discourse talk about very similar subjects concerning weight loss and obesity, without being grounded in research and data https://t.co/43UXKuvqy2

[saman rahmanian @saman]

6/ Our goal is never to either diminish other people’s life choices or to cause anyone harm by viewing our ad, but to start a conversation. We wrote more about the process behind the campaign here. We’re glad the conversation is happening and so are our patients.
https://t.co/8vZyGmhqvK

[saman rahmanian @saman]

1/ Our ads were recently slammed for being ‘too evocative’. I think our ads, and the coverage, are starting the exact conversation that we at Ro think is vital to have for patients. For decades, people have viewed obesity differently than other chronic diseases and the reaction to our ads continue to reaffirm this. Here are some sentiments I shared with our team today: https://t.co/aPQ5WR6t1o

[saman rahmanian @saman]

5/ We are not misleading. We don’t use humor. We are not making far fetched claims. We are simply showing patients, in empowered poses, using treatment for their chronic disease. If people are uncomfortable with them, what does that say about how we view obesity?

[saman rahmanian @saman]

Obesity isn’t a failing of self-control. Our new Body Program campaign spotlights obesity as a chronic condition that is worthy of high-quality care + effective treatment – and tells people that they can feel empowered to seek just that if they want to.
https://t.co/Pbbn0rgqZi

[saman rahmanian @saman]

Our team is driven by a mission to help our patients achieve their goals. Now Ro is tackling obesity—one of the biggest health challenges facing our patients and society. Learn more: https://t.co/eap7cFOsKz

[saman rahmanian @saman]

There’s a huge gap in obesity care. People are told that their weight is a failing of self-control or discipline. We know this could not be further from the truth. That’s why @ro built the Body Program. https://t.co/B5ey4jgwI7

[saman rahmanian @saman]

We saw an opportunity to help usher in a new era in weight loss—by using our direct-to-patient approach to expand access to effective GLP-1 treatments and marrying that with the unrivaled convenience offered by our vertically integrated platform.